(VIANEWS) – VEIDEKKE (VEI.OL), GRAM CAR CARRIERS (GCC.OL), FREY (FREY.PA) have the highest dividend yield stocks on this list.
| Financial Asset | Forward Dividend Yield | Updated (EST) |
|---|---|---|
| VEIDEKKE (VEI.OL) | 7.81% | 2024-02-04 07:31:29 |
| GRAM CAR CARRIERS (GCC.OL) | 7.21% | 2024-02-04 11:30:14 |
| FREY (FREY.PA) | 5.9% | 2024-02-04 07:46:29 |
| INNATE PHARMA (IPH.PA) | 4.64% | 2024-02-04 07:46:52 |
Several Euronext companies pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.
1. VEIDEKKE (VEI.OL)
7.81% Foward Dividend Yield
VEIDEKKE’s last close was kr96.40, 21.5% below its 52-week high of kr122.80. Intraday change was -1.12%.
Veidekke ASA operates as a construction and property development company. It operates through Construction Norway, Infrastructure Norway, Construction Sweden, Infrastructure Sweden, and Denmark/Hoffmann segments. The company operates as a construction contractor; executes civil engineering and renovation projects; and produces asphalt and aggregates, as well as operates in the public road maintenance market. It is also involved in the civil engineering, recycling, and asphalting projects, as well as constructs commercial and residential buildings. Veidekke ASA was founded in 1936 and is headquartered in Oslo, Norway.
Earnings Per Share
As for profitability, VEIDEKKE has a trailing twelve months EPS of kr8.
PE Ratio
VEIDEKKE has a trailing twelve months price to earnings ratio of 12.09. Meaning, the purchaser of the share is investing kr12.09 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 44.7%.
More news about VEIDEKKE.
2. GRAM CAR CARRIERS (GCC.OL)
7.21% Foward Dividend Yield
GRAM CAR CARRIERS’s last close was kr225.00, 4.05% under its 52-week high of kr234.50. Intraday change was -1.97%.
Gram Car Carriers ASA, through its subsidiaries, operates as a tonnage supplier worldwide. The company invests in and operates assets in the pure car and truck carrier shipping segment. It also offers commercial management services for the 19 owned carriers and 1 vessel managed by third party. The company was founded in 2006 and is based in Oslo, Norway.
Earnings Per Share
As for profitability, GRAM CAR CARRIERS has a trailing twelve months EPS of kr22.76.
PE Ratio
GRAM CAR CARRIERS has a trailing twelve months price to earnings ratio of 9.86. Meaning, the purchaser of the share is investing kr9.86 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 26.53%.
Dividend Yield
As stated by Morningstar, Inc., the next dividend payment is on Nov 7, 2023, the estimated forward annual dividend rate is 16.22 and the estimated forward annual dividend yield is 7.21%.
Volatility
GRAM CAR CARRIERS’s last week, last month’s, and last quarter’s current intraday variation average was 0.74%, 0.21%, and 1.62%.
GRAM CAR CARRIERS’s highest amplitude of average volatility was 1.63% (last week), 1.40% (last month), and 1.62% (last quarter).
Sales Growth
GRAM CAR CARRIERS’s sales growth is negative 86.1% for the ongoing quarter and 36.7% for the next.
Earnings Before Interest, Taxes, Depreciation, and Amortization
GRAM CAR CARRIERS’s EBITDA is 194.22.
More news about GRAM CAR CARRIERS.
3. FREY (FREY.PA)
5.9% Foward Dividend Yield
FREY’s last close was €27.00, 24.16% under its 52-week high of €35.60. Intraday change was 0%.
Frey SA engages in developing, owning, and managing commercial real estate assets primarily located in France. The company primarily operates environmental retail parks. As of December 31, 2010, its assets included 62,000 square meters. The company was formerly known as Immobiliere Frey SA and changed its name to Frey SA in June 2009. Frey SA was founded in 1983 and is based in Reims, France.
Earnings Per Share
As for profitability, FREY has a trailing twelve months EPS of €3.27.
PE Ratio
FREY has a trailing twelve months price to earnings ratio of 8.32. Meaning, the purchaser of the share is investing €8.32 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 9.92%.
Moving Average
FREY’s value is way under its 50-day moving average of €30.97 and way below its 200-day moving average of €32.93.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, FREY’s stock is considered to be overbought (>=80).
Revenue Growth
Year-on-year quarterly revenue growth grew by 18.2%, now sitting on 134.96M for the twelve trailing months.
Dividend Yield
As claimed by Morningstar, Inc., the next dividend payment is on May 15, 2023, the estimated forward annual dividend rate is 1.7 and the estimated forward annual dividend yield is 5.9%.
More news about FREY.
4. INNATE PHARMA (IPH.PA)
4.64% Foward Dividend Yield
INNATE PHARMA’s last close was €2.35, 38.16% below its 52-week high of €3.80. Intraday change was 0.21%.
Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; Avdoralimab (IPH5401), an Anti-C5aR Antibody; IPH5201, a blocking antibody that is in Phase 1 clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH4501, an antibody drug conjugates (ADC); and IPH65, a tetra-specific proprietary antibody. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.
Earnings Per Share
As for profitability, INNATE PHARMA has a trailing twelve months EPS of €-0.79.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -71.91%.
Revenue Growth
Year-on-year quarterly revenue growth declined by 11.8%, now sitting on 52.28M for the twelve trailing months.
Moving Average
INNATE PHARMA’s worth is under its 50-day moving average of €2.57 and way under its 200-day moving average of €2.82.
More news about INNATE PHARMA.
